{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:29:51Z","timestamp":1718238591402},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,12]]},"DOI":"10.7759\/cureus.62240","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T13:32:37Z","timestamp":1718199157000},"source":"Crossref","is-referenced-by-count":0,"title":["A Curious Case of Diabetic Ketoacidosis Secondary to Avelumab"],"prefix":"10.7759","author":[{"given":"Mafalda","family":"Costa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach DR","year":"1996","unstructured":"Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996, 271:1734-6. 10.1126\/science.271.5256.1734","journal-title":"Science"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3153","article-title":"Novel cancer immunotherapy agents with survival benefit: recent successes and next steps","volume":"11","author":"Sharma P","year":"2011","unstructured":"Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. 2011, 11:805-12. 10.1038\/nrc3153","journal-title":"Nat Rev Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer L","year":"2016","unstructured":"Zimmer L, Goldinger SM, Hofmann L, et al.. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016, 60:210-25. 10.1016\/j.ejca.2016.02.024","journal-title":"Eur J Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","author":"Sznol M","year":"2017","unstructured":"Sznol M, Postow MA, Davies MJ, et al.. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat Rev. 2017, 58:70-6. 10.1016\/j.ctrv.2017.06.002","journal-title":"Cancer Treat Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli AM","year":"2018","unstructured":"Stamatouli AM, Quandt Z, Perdigoto AL, et al.. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 2018, 67:1471-80. 10.2337\/dbi18-0002","journal-title":"Diabetes"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles T","year":"2020","unstructured":"Powles T, Park SH, Voog E, et al.. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020, 383:1218-30. 10.1056\/NEJMoa2002788","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes","volume":"7","author":"Kotwal A","year":"2019","unstructured":"Kotwal A, Haddox C, Block M, Kudva YC. Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. BMJ Open Diabetes Res Care. 2019, 7:e000591. 10.1136\/bmjdrc-2018-000591","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00728","article-title":"Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus","volume":"103","author":"Clotman K","year":"2018","unstructured":"Clotman K, Janssens K, Specenier P, Weets I, De Block CE. Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus. J Clin Endocrinol Metab. 2018, 103:3144-54. 10.1210\/jc.2018-00728","journal-title":"J Clin Endocrinol Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen J","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, et al.. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022, 33:1217-38. 10.1016\/j.annonc.2022.10.001","journal-title":"Ann Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider BJ","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021, 39:4073-126. 10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab048.847","article-title":"Immune checkpoint inhibitor mediated insulin dependent diabetes: observations at a cancer center","volume":"5","author":"Jeun R","year":"2021","unstructured":"Jeun R, Best C, Iyer P, et al.. Immune checkpoint inhibitor mediated insulin dependent diabetes: observations at a cancer center. J Endocr Soc. 2021, 5:A415-6. 10.1210\/jendso\/bvab048.847","journal-title":"J Endocr Soc"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller M","year":"2016","unstructured":"Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res. 2016, 22:886-94. 10.1158\/1078-0432.CCR-15-1136","journal-title":"Clin Cancer Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber JS","year":"2017","unstructured":"Weber JS, Hodi FS, Wolchok JD, et al.. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017, 35:785-92. 10.1200\/JCO.2015.66.1389","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01549-2","article-title":"Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis","volume":"18","author":"Zhou X","year":"2020","unstructured":"Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med. 2020, 18:87. 10.1186\/s12916-020-01549-2","journal-title":"BMC Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN bladder 100 trial after \u20212 years of follow-up","volume":"41","author":"Powles T","year":"2023","unstructured":"Powles T, Park SH, Caserta C, et al.. Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN bladder 100 trial after \u20212 years of follow-up. J Clin Oncol. 2023, 41:3486-92. 10.1200\/JCO.22.01792","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/258645-a-curious-case-of-diabetic-ketoacidosis-secondary-to-avelumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T13:32:41Z","timestamp":1718199161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/258645-a-curious-case-of-diabetic-ketoacidosis-secondary-to-avelumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,12]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.62240","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,12]]}}}